Keywords: ph, ii, results, genentech/xoma, raptiva, disappoint, psoriatic

Ph II results for Genentech/XOMA's Raptiva disappoint in psoriatic arthritis

Article | 29 March 2004

US biotechnology companies Genentech and XOMA have announced preliminary results of a randomized, placebo-controlled Phase II study with Raptiva (efalizumab) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Go to company listing

Related Drugs

Efalizumab

Raptiva

Go to drug listing